Zoltán Grosz

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 184 citations · Full text

Veterinary Medicine, Internal Medicine, Pharmacotherapy +3

Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients

Léna Szabó, Anita Gergely, Rita Jakus et al. · European Journal of Paediatric Neurology · 2020 · 59 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks

Priya S. Kishnani, Jordi Díaz‐Manera, António Toscano et al. · JAMA Neurology · 2023 · 55 citations · Full text

Life Sciences, Internal Medicine, Pharmacotherapy +8

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial

Wolfgang Köhler, Marc Engelen, Florian Eichler et al. · The Lancet Neurology · 2023 · 42 citations · Full text

Medicine, Endocrinology, Pharmacology +4

Genetic background of the hereditary spastic paraplegia phenotypes in Hungary — An analysis of 58 probands

Péter Balicza, Zoltán Grosz, Michael Gonzalez et al. · Journal of the Neurological Sciences · 2016 · 41 citations

Life Sciences, Genetics, Neurology +8